Venous thromboembolism is a disorder characterized by blood clotting in a blood vessel, resulting in a limitation of blood flow within the circulatory system. Venous thromboembolism is divided into two types: pulmonary embolism (PE) and deep vein thrombosis (DVT) (DVT). Deep vein thrombosis is caused primarily by blood clotting in the deep vein (commonly in the leg). Dilated blood vessels in the legs and chest, edema, fever, tachycardia, and dyspnea are all indications of venous thromboembolism. DVT most commonly affects the lower limbs, although it can also affect the mesenteric, upper extremities, pelvic veins, and cerebral veins.
The venous thromboembolism market is expanding rapidly due to a growth in the elderly population, an increase in government spending, and an increase in the incidence of venous thromboembolism, which is propelling the venous thromboembolism treatment market. Furthermore, an increase in surgical procedures such as hip and knee replacements, which are risk factors for venous thromboembolism disorders, as well as increased patient awareness, are likely to drive the venous thromboembolism market forward. However, the high cost of deep vein thrombosis treatment, significant unmet requirements of currently accessible treatment modalities, and unpleasant medication effects limit market expansion. Similarly, the existence of alternative therapies such as thrombectomy and percutaneous methods, as well as demanding regulatory clearances, are impeding the growth of the venous thromboembolism market.